文献速递白血病

成人急性髓系白血病中p53蛋白功能失调的多样性:对诊断检查与治疗的启示

Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.
PubMed 文献 · Blood · 2017-06-12

本文综述成人急性髓系白血病(AML)中p53功能失调的多样性,指出TP53突变在初诊AML中不足十分之一,而野生型p53的非突变性异常在多种AML中可能相当常见,其影响可能被低估。作者主张对成人AML评估共存的p53异常,结合TP53基因分型与p53蛋白功能评估以精准判定p53状态,并提出基于p53的诊断检查新流程以辅助治疗选择。

要点

  • TP53突变在初诊AML中不足十分之一,而实体瘤中超过一半病例存在TP53突变。
  • 野生型p53因非突变性异常导致的功能失调在多种AML中似乎相当常见,其影响可能被低估。
  • 作者主张对成人AML评估共存的p53异常,并据此提出基于p53的诊断检查流程。

核心结论

  • 作者主张对成人AML评估共存的p53异常,不仅关注突变型p53的致癌功能获得,也关注非突变性野生型p53失活的机制。
  • 针对患者个体的TP53基因分型联合p53蛋白功能评估,可能有助于精准判定AML的p53状态,从而制定合理的基于p53的精准治疗。
  • 阐明p53功能失调的机制将更好地指导目前考虑用于AML的p53靶向治疗,并提出基于p53的诊断检查新流程以辅助治疗选择。

研究设计与样本

  • 本文为综述,围绕AML遗传、表观遗传、演化与临床多样性中p53功能失调的作用进行论述,未报告检索范围。

主要发现

  • 在人类实体瘤中TP53突变见于超过一半的病例,而在初诊AML中TP53突变发生不足十分之一。
  • 野生型p53因非突变性p53异常导致的功能失调在多种AML中似乎相当常见,其影响可能比目前认识到的更大。
  • p53对造血干细胞功能至关重要,其异常影响AML的演化、生物学与治疗反应,通常预测预后不良。

临床怎么用

  • 作者主张对成人AML进行共存的p53异常评估。
  • 作者提出采用患者个体TP53基因分型联合p53蛋白功能评估以判定p53状态。
  • 作者提出一种基于p53的AML诊断检查新流程,旨在辅助基于p53的治疗选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The heterogeneous nature of acute myeloid leukemia (AML) and its poor prognosis necessitate therapeutic improvement. Current advances in AML research yield important insights regarding AML genetic, epigenetic, evolutional, and clinical diversity, all in which dysfunctional p53 plays a key role. As p53 is central to hematopoietic stem cell functions, its aberrations affect AML evolution, biology, and therapy response and usually predict poor prognosis. While in human solid tumors TP53 is mutated in more than half of cases, TP53 mutations occur in less than one tenth of de novo AML cases. Nevertheless, wild-type (wt) p53 dysfunction due to nonmutational p53 abnormalities appears to be rather frequent in various AML entities, bearing, presumably, a greater impact than is currently appreciated. Hereby, we advocate assessment of adult AML with respect to coexisting p53 alterations. Accordingly, we focus not only on the effects of mutant p53 oncogenic gain of function but also on the mechanisms underlying nonmutational wtp53 inactivation, which might be of therapeutic relevance. Patient-specific TP53 genotyping with functional evaluation of p53 protein may contribute significantly to the precise assessment of p53 status in AML, thus leading to the tailoring of a rationalized and precision p53-based therapy. The resolution of the mechanisms underlying p53 dysfunction will better address the p53-targeted therapies that are currently considered for AML. Additionally, a suggested novel algorithm for p53-based diagnostic workup in AML is presented, aiming at facilitating the p53-based therapeutic choices.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Prokocimer M, Molchadsky A, Rotter V, et al. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. Blood. 2017. PMID: 28607134. doi:10.1182/blood-2017-02-763086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。